Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.

Abstract

Brain glutamate has been shown to play an important role in reinstatement to drug seeking, a behavior considered to be of relevance to relapse to drug taking in humans. Therefore, glutamate receptors, in particular metabotropic glutamate (mGlu) receptors, have become important targets for medication development for the treatment of drug dependence. In this review article, we focus on the mGlu7 receptor subtype, and discuss recent findings with AMN082, a selective mGlu7 receptor allosteric agonist, in animal models with relevance to drug dependence. Systemic or local administration of AMN082 into the nucleus accumbens (NAc), a critical brain region involved in reward and drug dependence processes, inhibited the reinforcing and motivational effects of cocaine, heroin and ethanol, as assessed by the intravenous drug self-administration procedure. In addition, AMN082 inhibited the reward-enhancing effects induced by cocaine, as assessed in the intracranial self-stimulation procedure, and cocaine- or cue-induced reinstatement of drug-seeking behavior. In vivo microdialysis studies indicated that systemic or intra-NAc administration of AMN082 significantly decreased extracellular γ-aminobutyric acid (GABA) and elevated extracellular glutamate, but had no effect on extracellular dopamine in the NAc, suggesting that a non-dopaminergic mechanism underlies the effects of AMN082 on the actions of cocaine. Further, data indicated that AMN082-induced changes in glutamate were the net effect of two actions: one is the direct inhibition of glutamate release by activation of mGlu7 receptors on glutamatergic neurons; another is the indirect increases of glutamate release mediated by decreases in GABA transmission. These increases in extracellular glutamate functionally antagonized cocaine-induced inhibition of NAc-ventral pallidum GABAergic neurotransmission, and therefore, the rewarding effects of cocaine. In addition, elevated extracellular glutamate activated presynaptic mGlu2/3 autoreceptors which in turn inhibited cocaine priming- or cue-induced enhancement of glutamate release and reinstatement of drug-seeking behavior. Taken together, these findings suggest that the mGlu7 receptor is an important target for medication development for the treatment of drug dependence. AMN082 or other mGlu7 receptor allosteric agonists may have potential as novel pharmacotherapies for cocaine addiction. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.

• Authors: Xia Li, Zheng-Xiong Xi, Athina Markou
• Journal: Neuropharmacology (Neuropharmacology) Vol. 66 Pg. 12-23 (Mar 2013) ISSN: 1873-7064 [Electronic] England
• PMID: 22546614 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2012 Elsevier Ltd. All rights reserved.

Chemical References

• Benzhydryl Compounds
• N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride
• Receptors, Metabotropic Glutamate
• metabotropic glutamate receptor 2
• metabotropic glutamate receptor 7

Topics

• Animals
• Behavior, Addictive (drug therapy)
• Benzhydryl Compounds (therapeutic use)
• Cocaine-Related Disorders (drug therapy, physiopathology)
• Disease Models, Animal
• Globus Pallidus (drug effects, physiology)
• Mental Disorders (physiopathology)
• Molecular Targeted Therapy (methods)
• Nucleus Accumbens (drug effects, physiology)
• Receptors, Metabotropic Glutamate (agonists, physiology)
• Synaptic Transmission (drug effects, physiology)